Eurand has entered into a development and license agreement with GlaxoSmithKline to use its Microcaps taste-masking and AdvaTab oral disintegration tablet technologies to develop a new formulation of an undisclosed GSK product. Under the terms of the agreement, GSK will fund the development of the product and Eurand will receive royalties on product sales. GSK will have exclusive commercialization rights in the U.S., and both companies will have certain rights to commercialize the product o...